Study Identifies Biological Age Acceleration as Independent Mortality Predictor in Early Cardio-Kidney-Metabolic Cohorts

An NHANES cohort study of 16,837 participants demonstrates that biological age acceleration, particularly Phenotypic Age Acceleration, independently predicts all-cause and cardiovascular mortality in early-stage cardio-kidney-metabolic syndrome.

Researchers analyzed prospective data from 16,837 participants in the National Health and Nutrition Examination Survey (NHANES) across eight cycles to evaluate the prognostic value of biological age acceleration (BAA) in Cardio-Kidney-Metabolic (CKM) stages 0–3.

Biological age was estimated using two standard-biomarker algorithms: the Klemera-Doubal Method (KDM-BA) and the Phenotypic Age (PA) algorithm, with residuals determining biological age acceleration.

Over a median follow-up of 11.33 years, 10.8% of the weighted population died. After fully adjusting for demographics, lifestyles, and medications, KDM-BAA positivity increased the risk of all-cause, CVD, and non-CVD mortality by 41%, 74%, and 31%, respectively.

Phenotypic Age Acceleration (PAA) positivity demonstrated even stronger risk elevations, increasing the risk of all-cause mortality by 103%, CVD mortality by 79%, and non-CVD mortality by 112%.

Using nine selected features including PAA, the investigators constructed a LASSO-Cox-based mortality nomogram that achieved favorable validation AUCs of 0.765 at 10 years and 0.757 at 20 years.

Individuals in CKM stages 0 to 3—encompassing obesity, metabolic abnormalities, or early-stage renal impairment without clinical cardiovascular events—are traditionally categorized as low-risk and are rarely prioritized for aggressive preventive measures.

The findings suggest that biological age acceleration serves as an independent, microscopic indicator of systemic deterioration, likely reflecting underlying chronic low-grade inflammation and immunosenescence that macroscopic CKM staging fails to fully capture.

The clinical utility of KDM-BA and PA algorithms is highly scalable compared to DNA-methylation clocks like GrimAge, as they leverage common clinical markers including CRP, RDW, creatinine, and systolic blood pressure, making them viable for cost-effective primary care integration.

This prospective validation strengthens the clinical rationale for preventative medicine providers and digital health platforms targeting the pre-symptomatic stages of metabolic aging.

The distinct predictive superiority of the inflammation-inclusive Phenotypic Age metric over the KDM method highlights a growing market opportunity for diagnostics and therapeutics targeting the metabolic-inflammatory axis, such as low-grade systemic inflammation and cellular senescence.

Future clinical trials evaluating whether therapeutics targeting metabolic or inflammatory aging pathways can successfully reverse biological age acceleration and consequently reduce long-term mortality in CKM cohorts.